Drug Profile
IPX 233
Alternative Names: IPX-233; IPX233 ER C0003; IPX233-C0001; IPX233-C0002; IPX233-T0001; IPX233-T0002Latest Information Update: 15 May 2018
Price :
$50
*
At a glance
- Originator Impax Pharmaceuticals
- Class
- Mechanism of Action Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Attention-deficit hyperactivity disorder
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 01 Jan 2015 Impax Pharmaceuticals terminates phase I trial of an extended release capsule in Healthy volunteers in Australia (ACTRN12614000518662)
- 01 Aug 2014 IPX 233 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions